Drug intelligence / Profile preview

VB25

Development stage: Preclinical
Lead developer: 深圳扬厉医药
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

VB25 is a small interfering RNA (siRNA) therapeutic candidate being developed by Zhejiang Yangli Pharmaceutical Technology (also known as VyBio) for the treatment of diabetes. As part of the company's cardiovascular, renal, and metabolic (CVRM) pipeline, VB25 is designed to utilize RNA interference to silence the expression of a specific, currently undisclosed gene target involved in the pathogenesis or progression of diabetes. The drug is currently in the discovery and preclinical stage of development, aiming to provide a targeted approach to managing metabolic dysfunction.

Beyond the preview

Go deeper on VB25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB25.

Explore the full profile